Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Routine radiopharmaceutical production for positron emission tomography in a clinical setting

Conference · · Trans. Am. Nucl. Soc.; (United States)
OSTI ID:5007394

With the development of positron emission tomography (PET), many cellular processes can now be investigated in humans. To perform this task, positron-emitting radioisotopes, which decay by emission of coincidence photons externally detected after positron annihilation, are used in PET. Thus, biochemically and pharmacologically active compounds can be labeled with cyclotron-produced positron-emitting radioisotopes of carbon, nitrogen, oxygen, and fluorine to probe enzyme reaction rates, membrane transport, metabolism, synthesis processes, and various pharmacological parameters. The development of PET technology for clinical applications requires not only the development of a minicyclotron technology, but also the targetry and reliable synthetic procedures for labeled compounds, all of which must be finally integrated into automated delivery systems. Although an integrated unit (cyclotron, chemistry, imaging device) specially designed for PET in clinical settings has never been developed, the work in progress in this area indicates that its implementation is immediately possible.

Research Organization:
Univ. of California, Los Angeles
OSTI ID:
5007394
Report Number(s):
CONF-851115-
Journal Information:
Trans. Am. Nucl. Soc.; (United States), Journal Name: Trans. Am. Nucl. Soc.; (United States) Vol. 50; ISSN TANSA
Country of Publication:
United States
Language:
English